ev3, FoxHollow Merger Creates Peripheral Vascular Leviathan
This article was originally published in The Gray Sheet
Executive Summary
Endovascular device makers ev3 and FoxHollow are combining their respective strong European and U.S. sales forces in a merger announced July 22
You may also be interested in...
FoxHollow Integration Problems Plague ev3 In First Quarter
Endovascular device firm ev3's failure to meet first-quarter 2008 revenue targets is being blamed on unexpected challenges in assimilating the FoxHollow Technologies sales force
FoxHollow Integration Problems Plague ev3 In First Quarter
Endovascular device firm ev3's failure to meet first-quarter 2008 revenue targets is being blamed on unexpected challenges in assimilating the FoxHollow Technologies sales force
People In Brief
Edwards Lifesciences restructuring: Cardiovascular technology firm announces planned mid-year departures of corporate VPs Anita B. Bessler, Stuart L. Foster and Alex Martin, along with "strengthened alignment" into a business-unit organizational structure. Corporate VPs Donald E. Bobo, Paul C. Redmond, Carlyn D. Solomon and Larry L. Wood will take on additional U.S. sales, marketing and operational duties in their units, reporting to CEO Michael A. Mussallem. Bessler and Foster will continue in advisory roles with the company